XML 22 R9.htm IDEA: XBRL DOCUMENT
v3.8.0.1

GOODWILL AND OTHER INTANGIBLE ASSETS | 9 Months Ended
--- | ---
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2017 were as follows:
| Specialty Surgical Solutions |  | Orthopedics and Tissue Technologies |  | Total
| (In thousands)
Goodwill at December 31, 2016 | $ | 284,358 |  |  | $ | 226,213 |  |  | $ | 510,571 |
Derma Sciences acquisition | — |  |  | 70,424 |  |  | 70,424 |
TGX Medical acquisition | 641 |  |  | — |  |  | 641 |
Transfer to assets held for sale | (2,861 | ) |  | — |  |  | (2,861 | )
Foreign currency translation | 4,400 |  |  | 4,768 |  |  | 9,168 |
Balance, September 30, 2017 | $ | 286,538 |  |  | $ | 301,405 |  |  | $ | 587,943 |
The components of the Company’s identifiable intangible assets were as follows:
| September 30, 2017
| Weighted Average Life |  | Cost |  | Accumulated Amortization |  | Net
| (Dollars in thousands)
Completed technology | 17 years |  | $ | 492,380 |  |  | $ | (114,996 | ) |  | $ | 377,384 |
Customer relationships | 13 years |  | 234,020 |  |  | (88,944 | ) |  | 145,076 |
Trademarks/brand names | 28 years |  | 105,690 |  |  | (22,336 | ) |  | 83,354 |
Supplier relationships | 27 years |  | 34,721 |  |  | (14,735 | ) |  | 19,986 |
All other (1) | 5 years |  | 11,675 |  |  | (3,423 | ) |  | 8,252 |
|  |  | $ | 878,486 |  |  | $ | (244,434 | ) |  | $ | 634,052 |
| December 31, 2016
| Weighted Average Life |  | Cost |  | Accumulated Amortization |  | Net
| (Dollars in thousands)
Completed technology | 17 years |  | $ | 479,964 |  |  | $ | (94,991 | ) |  | $ | 384,973 |
Customer relationships | 12 years |  | 152,335 |  |  | (77,005 | ) |  | 75,330 |
Trademarks/brand names | 30 years |  | 90,507 |  |  | (19,158 | ) |  | 71,349 |
Supplier relationships | 27 years |  | 34,721 |  |  | (13,664 | ) |  | 21,057 |
All other (1) | 5 years |  | 10,806 |  |  | (2,340 | ) |  | 8,466 |
|  |  | $ | 768,333 |  |  | $ | (207,158 | ) |  | $ | 561,175 |
(1) | At September 30, 2017 and December 31, 2016, all other included in-process research and development ("IPR&D") of $1.0 million in both periods, which was indefinite-lived.
During the third quarter of 2017, the Company recorded an impairment charge of $3.3 million in cost of goods sold related to completed technology assets acquired from Tarsus Medical, Inc. ("Tarsus Technology"), since the underlying product will no longer be sold. Tarsus Technology was included in the Orthopedic and Tissue Technology segment. Based on quarter-end exchange rates, annual amortization expense (including amounts reported in cost of product revenues, but excluding any possible future amortization associated with acquired in-process research and development) is expected to be approximately $48.4 million in 2017, $49.1 million in 2018, $49.0 million in 2019, $48.9 million in 2020, $47.9 million in 2021, $44.4 million in 2022 and $493.7 million thereafter. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition using an income or cost approach.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration